Ken Griffin Biomarin Pharmaceutical Inc Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$69.02 - $93.84 $5.3 Million - $7.21 Million	-76,800 Reduced 22.84%	259,400 $18.2 Million
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $16.5 Million - $20.4 Million	221,100 Added 192.09%	336,200 $27.7 Million
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $1.36 Million - $1.6 Million	16,200 Added 16.38%	115,100 $10.1 Million
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $17.3 Million - $22.4 Million	-227,600 Reduced 69.71%	98,900 $9.54 Million
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $9.7 Million - $10.8 Million	114,000 Added 53.65%	326,500 $28.9 Million
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $1.9 Million - $2.2 Million	21,900 Added 11.49%	212,500 $18.4 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $8.78 Million - $11.7 Million	100,100 Added 110.61%	190,600 $18.5 Million
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $12 Million - $16.1 Million	-148,200 Reduced 62.09%	90,500 $9.37 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $1.54 Million - $1.82 Million	-18,800 Reduced 7.3%	238,700 $20.2 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.